

**VIA EDGAR**

February 11, 2019

United States Securities and Exchange Commission  
Division of Corporation Finance  
Mail Stop 4561  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Todd Schiffman

**Re: Xeris Pharmaceuticals, Inc.  
Acceleration Request for Registration Statement on Form S-1  
File No. 333-229600**

Dear Mr. Schiffman

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “**Act**”), Xeris Pharmaceuticals, Inc. (the “**Company**”) hereby requests that the effective date of the above-referenced registration statement (the “**Registration Statement**”) be accelerated to February 13, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Joseph Theis at (617) 570-1928. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “**Commission**”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Joseph Theis, by facsimile to (617) 801-8864.

If you have any questions regarding this request, please contact Joseph Theis of Goodwin Procter LLP at (617) 570-1928.

Sincerely,

XERIS PHARMACEUTICALS, INC.

/s/ Barry Deutsch

---

Barry Deutsch  
Chief Financial Officer

cc: Barry Deutsch, Chief Financial Officer, *Xeris Pharmaceuticals, Inc.*  
Joseph Theis, Jr., Esq., *Goodwin Procter LLP*